Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer

Burcak Yoldas; Cem Ozer; Ozlem Ozen; Tuba Canpolat; Isilay Dogan; Thomas S. Griffith; Salih Sanlioglu; Levent N. Ozluoglu

doi:10.1002/hed.21598

Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer

Burcak Yoldas, Cem Ozer, Ozlem Ozen, Tuba Canpolat, Isilay Dogan, Thomas S. Griffith, Salih Sanlioglu, Levent N. Ozluoglu

Urology

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Background. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC). Methods. Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry. Results. An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN). Conclusions. TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC. © 2010 Wiley Periodicals, Inc. Head Neck, 2010

Original language	English (US)
Pages (from-to)	1278-1284
Number of pages	7
Journal	Head and Neck
Volume	33
Issue number	9
DOIs	https://doi.org/10.1002/hed.21598
State	Published - Sep 1 2011

Keywords

TRAIL
TRAIL receptor
clinical and pathologic staging
head and neck cancer
molecular diagnostics

Access

10.1002/hed.21598

Fingerprint Dive into the research topics of 'Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer'. Together they form a unique fingerprint.

Cite this

@article{292449540240497aaa31353150b17414,

title = "Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer",

abstract = "Background. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC). Methods. Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry. Results. An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN). Conclusions. TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC. {\textcopyright} 2010 Wiley Periodicals, Inc. Head Neck, 2010",

keywords = "TRAIL, TRAIL receptor, clinical and pathologic staging, head and neck cancer, molecular diagnostics",

author = "Burcak Yoldas and Cem Ozer and Ozlem Ozen and Tuba Canpolat and Isilay Dogan and Griffith, {Thomas S.} and Salih Sanlioglu and Ozluoglu, {Levent N.}",

year = "2011",

month = sep,

day = "1",

doi = "10.1002/hed.21598",

language = "English (US)",

volume = "33",

pages = "1278--1284",

journal = "Head and Neck Surgery",

issn = "1043-3074",

publisher = "Wiley-Liss Inc.",

number = "9",

}

TY - JOUR

T1 - Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer

AU - Yoldas, Burcak

AU - Ozer, Cem

AU - Ozen, Ozlem

AU - Canpolat, Tuba

AU - Dogan, Isilay

AU - Griffith, Thomas S.

AU - Sanlioglu, Salih

AU - Ozluoglu, Levent N.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC). Methods. Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry. Results. An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN). Conclusions. TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC. © 2010 Wiley Periodicals, Inc. Head Neck, 2010

AB - Background. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC). Methods. Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry. Results. An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN). Conclusions. TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC. © 2010 Wiley Periodicals, Inc. Head Neck, 2010

KW - TRAIL

KW - TRAIL receptor

KW - clinical and pathologic staging

KW - head and neck cancer

KW - molecular diagnostics

UR - http://www.scopus.com/inward/record.url?scp=80051743553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051743553&partnerID=8YFLogxK

U2 - 10.1002/hed.21598

DO - 10.1002/hed.21598

M3 - Article

C2 - 21837697

AN - SCOPUS:80051743553

VL - 33

SP - 1278

EP - 1284

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 1043-3074

IS - 9

ER -